Literature DB >> 17311768

Peripheral gangrene associated with Kawasaki disease and successful management using prostacycline analogue: a case report.

Omer Faruk Dogan1, Ates Kara, Ilker Devrim, Hasan Tezer, Nesrin Besbas, Seza Ozen, Gulten Secmeer, Cem Yorgancioglu, Erkmen Boke.   

Abstract

We report a case of child-onset Kawasaki disease that presented as a prolonged fever and manifested with coronary aneurysms and peripheral gangrene of the lower limbs. Therapy with intravenous immunoglobulins, corticosteroids, aspirin, anticoagulants, and ilomedine, a prostacyclin analogue, resulted in rapid improvement in the patient's condition without extremity loss. Those treating patients with Kawasaki disease must be aware of possible vascular ischemia in the disease process that is reversible by early intervention treatments, including the use of a prostacycline analogue, that improve quality of life.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17311768     DOI: 10.1532/HSF98.20061151

Source DB:  PubMed          Journal:  Heart Surg Forum        ISSN: 1098-3511            Impact factor:   0.676


  3 in total

1.  Peripheral Gangerene, an Unusual Presentation of Infantile Kawasaki: A Case Report and Literature Review.

Authors:  Fatemeh Tahghighi; Maryam Bakhtiari Koohsorkhi; Vahid Ziaee
Journal:  Case Rep Rheumatol       Date:  2021-04-13

Review 2.  Kawasaki disease complicated by peripheral artery thrombosis: a case report and literature review.

Authors:  Nanjun Zhang; Li Yu; Zhongxian Xiong; Yimin Hua; Hongyu Duan; Lina Qiao; Kaiyu Zhou; Chuan Wang
Journal:  Pediatr Rheumatol Online J       Date:  2022-09-05       Impact factor: 3.413

3.  Plasma Prostaglandin E2 Levels Correlated with the Prevention of Intravenous Immunoglobulin Resistance and Coronary Artery Lesions Formation via CD40L in Kawasaki Disease.

Authors:  Ho-Chang Kuo; Chih-Lu Wang; Kuender D Yang; Mao-Hung Lo; Kai-Sheng Hsieh; Sung-Chou Li; Ying-Hsien Huang
Journal:  PLoS One       Date:  2016-08-15       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.